Martin Hey-Mogensen
Director Novo Nordisk
Seminars
Wednesday 28th October 2026
Panel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial Scale
4:15 pm
- Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
- Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
- Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market
Wednesday 28th October 2026
Exploring Energy Expenditure as an Alternative Method of Obesity Treatment
2:30 pm
- Highlighting mode of actions to increase energy expenditure
- Targeting bioenergetics for safe and tolerable increase in energy expenditure to treat metabolic diseases
- Determining which tissue to target to ensure enough efficacy for different therapeutic areas
